HLS Therapeutics Inc.
TSX:HLS.TO · Toronto Stock Exchange
-$0.11 today
Vol 0.00M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-20.5%
avg -13.9%
ROIC
-3.5%
avg -2.8%
ROA
-9.2%
avg -7.3%
Analysis
ROIC is currently the strongest return metric at -3.5% versus its period average of -2.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Craig Stuart Millian | Chief Executive Officer & Director | $1.36M | — | 58 | — | — |
Brian T. Walsh | Chief Commercial Officer | $705,151.00 | — | — | — | — |
John Hanna | Chief Financial Officer & Non-Independent Director | $673,498.00 | — | 61 | — | — |
Ryan C. Lennox | Senior Vice President of Legal, HR & Compliance and Corporate Secretary | $548,263.00 | — | 45 | — | — |
Jason A. Gross | Vice President of Scientific Affairs | $416,645.00 | — | 61 | — | — |
David Spence | Vice President & Corporate Controller | — | — | 58 | — | — |
Dave Mason | Investor Relations Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -44.5% | +10.9% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -44.5% over three years. Forward estimates point to Revenue at +10.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Auxly Cannabis Group Inc.
TSX:XLY.TO
$257.70M
Quipt Home Medical Corp.
QIPT.TO
$221.44M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
BioSyent Inc.
RX.V
$160.02M
Grown Rogue International Inc.
GRIN.CN
$149.96M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Planet 13 Holdings Inc.
PLTH.CN
$60.79M
BioNxt Solutions Inc.
BNXT.CN
$48.08M
Who manages HLS.TO?
HLS Therapeutics Inc. (HLS.TO) lists 7 active executives. The top listed executive is Brian T. Walsh, Chief Commercial Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.